愛美醫療 FOLD 深 滬
已收盤 04-27 16:00:00 美东时间
14.49
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 14.49
- 總市值 45.50亿
- 52周最高 14.50
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 5.51
- 委 比 0.00%
- 總股本 3.14亿
- 歷史最高 25.39
- 量 比 0
- 振 幅 0.00%
- 歷史最低 1.765
- 每 手 1
- 風險率 3.25%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多爱美医疗15分钟走势图出现MACD死叉及看跌光头光脚阴线形态
截至2026年6月29日15时15分，爱美健康15分钟级别走势图形成MACD死叉形态与看跌光头光脚阴线形态。 相关信号显示该股股价存在延续下行可能性，当前市场由...
06-30 03:19
爱美医疗15分钟走势图触发RSI超卖 KDJ金叉
爱美医疗15分钟级别走势图显现技术面利好信号：相对强弱指标（RSI）进入超卖区间，数值为32.31，随机指标（KDJ）于2026年6月24日15:15形成金叉...
06-25 03:23
Capricor names Michael Maurer chief commercial officer
Capricor names Michael Maurer chief commercial officer Capricor Therapeutics appointed Michael Maurer as chief commercial officer, effective immediately, to strengthen launch readiness for Deramiocel in Duchenne muscular dystrophy. Maurer brings about two decades in rare-disease commercialization, p
05-29 09:58
BioMarin Pharmaceutical Receives Approval From France's Ministry Of Economics And Finance For Proposed Merger With Amicus Therapeutics
https://www.sec.gov/ix?doc=/Archives/edgar/data/1048477/000119312526173770/d139584d8k.htm
04-24 04:56
Top 10 Healthcare stocks by forward P/E: From Capricor's 418x to Alignment Healthcare's 48x
A Bank of America Global Research chart tracking healthcare R&D-to-sales ratios and relative forward PE versus the S&P 500 from 1990 to March 2026 shows both metrics declining in tandem over decades, ...
04-17 04:04
新浪财经ESG：爱美医疗 MSCI（明晟）ESG评级调降至B
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
03-24 10:13
Amicus Therapeutics President and CEO Bradley L Campbell Disposes of Common Shares
Amicus Therapeutics President and CEO Bradley L Campbell Disposes of Common Shares Bradley L. Campbell, President and CEO and a director of Amicus Therapeutics Inc., reported a disposal of common shares. The full filing can be accessed through the link below. Disclaimer: This news brief was created
03-05 08:55
BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients
The FDA approved BioMarin's supplemental BLA for Palynziq, a treatment for PKU in adolescents 12 and older.
03-02 19:10
Legal Challenges Loom Over Amicus–BioMarin Merger, Raising Execution and Shareholder Risks
Amicus Therapeutics (FOLD) has disclosed a new risk, in the Litigation & Le...
02-22 14:05
